Comparison of haemodialysis patients and non-haemodialysis patients with respect to clinical characteristics and 3-year clinical outcomes after sirolimus-eluting stent implantation: insights from the Japan multi-centre post-marketing surveillance registry
Open Access
- 31 December 2010
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 32 (7), 829-837
- https://doi.org/10.1093/eurheartj/ehq480
Abstract
Long-term outcomes after sirolimus-eluting stent (SES) implantation in haemodialysis (HD) patients have remained controversial. We investigated the impact of HD on outcomes after SES implantation. We analysed the data on 2050 patients who underwent SES implantation in a multi-centre prospective registry in Japan. Three-year clinical outcomes were compared between the HD group (n = 106) and the non-haemodialysis (NH) group (n = 1944). At the 3-year clinical follow-up, the rates of unadjusted cardiac mortality (HD: 16.3 vs. NH: 2.3%) and target-lesion revascularization (TLR) (HD: 19.4 vs. NH: 6.6%) were significantly higher in the HD group than the NH group (P < 0.001). Although HD group had a numerically higher stent thrombosis rate, the difference in stent thrombosis between the two groups (HD: 2.0 vs. NH: 0.7%) did not reach statistical significance. Using Cox's proportional-hazard models with propensity score adjustment for baseline differences, the HD group had higher risks of TLR [HD: 16.3 vs. NH: 6.1%; hazard ratio, 2.83; 95% confidence interval (CI): 1.62–4.93, P = 0.0003] and cardiac death (HD: 12.3 vs. NH: 2.3%; hazard ratio, 5.51; 95% CI: 2.58–11.78, P < 0.0001). The consistent results of analyses, whether unadjusted or adjusted for other baseline clinical and procedural differences, identify HD as an independent risk factor for cardiac death and TLR. Percutaneous coronary intervention with SES in HD patients has a higher incidence of repeat revascularization and mortality compared with those in NH patients. Haemodialysis appears to be strongly associated with mortality and repeat revascularization even after SES implantation.This publication has 30 references indexed in Scilit:
- Drug-eluting stents in patients with end-stage renal disease: Meta-analysis and systematic review of the literatureCatheterization and Cardiovascular Interventions, 2010
- Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent ImplantationCirculation, 2009
- Stent fracture, an incidental finding or a significant marker of clinical in‐stent restenosis?Catheterization and Cardiovascular Interventions, 2008
- A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label IndicationsThe New England Journal of Medicine, 2008
- A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery DiseaseJournal of the American College of Cardiology, 2007
- Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: An intravascular ultrasound studyJournal of the American College of Cardiology, 2005
- Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary interventionThe American Journal of Cardiology, 2004
- Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”Circulation, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryThe New England Journal of Medicine, 2003
- Long-term outcome of dialysis patients in the United States with coronary revascularization proceduresKidney International, 1999